問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Hematology & Oncology

Division of General Internal Medicine

Division of Others-

National Taiwan University Hospital Hsin-Chu Branch (在職)

Division of Hematology & Oncology

更新時間：2023-09-19

周聖傑Chou, Sheng-chieh
  • Principal Investigator
  • Clinical Trial Experience (year) 12 years 9 個月

  • 104483@ntuh.gov.tw

Recruiting Trial

70Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

周聖傑

List

127Cases

2021-09-30 - 2022-12-31

Others

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Terminated3Sites

2019-12-01 - 2020-05-12

Phase II

Completed
A Phase II, Single Arm, Multicenter Open Label Trial to Determine the Efficacy and Safety of Tisagenlecleucel (CTL019) in Adult Patients With Refractory or Relapsed Follicular Lymphoma

  • Condition/Disease

    Refractory or Relapsed Follicular Lymphoma

  • Test Drug

    CTL019

Participate Sites
1Sites

Terminated1Sites

2021-08-01 - 2026-06-30

Others

Active

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

2022-02-01 - 2026-12-31

Phase III

Active

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-08-01 - 2021-09-10

Phase III

Completed
Tisagenlecleucel Versus Standard of Care in Adult Patients With Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma: A Randomized, Open Label, Phase III Trial (BELINDA)

  • Condition/Disease

    Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma

  • Test Drug

    CTL019

Participate Sites
1Sites

Recruiting1Sites

2019-08-01 - 2024-07-15

Phase II

Completed
A Randomized, Double-blind, Placebo-controlled Phase II Multi-center Study of Intravenous MBG453 Added to Hypomethylating Agents in Adult Subjects With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R Criteria

  • Condition/Disease

    Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS)

  • Test Drug

    MBG453

Participate Sites
2Sites

Recruiting2Sites

2017-12-01 - 2023-12-31

Phase II

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2020-11-01 - 2035-05-31

Phase III

Active
Long Term Follow-Up of Patients Exposed to Lentiviral-Based CAR T-Cell Therapy

  • Condition/Disease

    B-cell Non-Hodgkin Lymphoma

  • Test Drug

    CTL019

Participate Sites
1Sites

Recruiting1Sites

2020-04-13 - 2024-11-19

Phase III

Completed
A Randomized, Double-blind, Placebo-controlled Phase III Multi-center Study of Azacitidine With or Without MBG453 for the Treatment of Patients With Intermediate, High or Very High Risk Myelodysplastic Syndrome (MDS) as Per IPSS-R, or Chronic Myelomonocytic Leukemia-2 (CMML-2)

  • Condition/Disease

    myelodysplastic syndrome (MDS)/CMML-2

  • Test Drug

    MBG453

Participate Sites
7Sites

Recruiting7Sites

2022-02-28 - 2025-08-18

Phase III

Completed

  • Condition/Disease

  • Test Drug

Participate Sites
1Sites

Recruiting1Sites

1 3 4 5 6 7 13
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB